PacBio Files 2023 10-K, Highlighting Strategic Progress and Financial Performance

Ticker: PACB · Form: 10-K · Filed: Feb 28, 2024 · CIK: 1299130

Sentiment: mixed

Topics: 10-K, Revenue, Net Loss, Genomics, Financials

TL;DR

<b>PacBio's 2023 10-K reveals a revenue dip in products but growth in services, alongside an increased net loss and a strong balance sheet with no debt.</b>

AI Summary

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed a Annual Report (10-K) with the SEC on February 28, 2024. PacBio reported total revenue of $273.5 million for the fiscal year ended December 31, 2023. Product revenue for 2023 was $198.8 million, a decrease of 11% compared to $223.4 million in 2022. Service and other revenue increased by 10% to $74.7 million in 2023 from $68.0 million in 2022. The company's net loss for 2023 was $233.1 million, compared to a net loss of $217.7 million in 2022. Total assets as of December 31, 2023, were $1.03 billion, with total debt at $0.

Why It Matters

For investors and stakeholders tracking PACIFIC BIOSCIENCES OF CALIFORNIA, INC., this filing contains several important signals. The decline in product revenue suggests potential market challenges or a shift in sales cycles for their core instrumentation. The increase in service revenue indicates a growing recurring revenue stream, which can provide more stability and predictability.

Risk Assessment

Risk Level: medium — PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shows moderate risk based on this filing. The company reported an increased net loss in 2023 ($233.1M vs $217.7M in 2022) and a decrease in product revenue, indicating potential headwinds in core business segments.

Analyst Insight

Investors should monitor the company's ability to reverse the product revenue decline and leverage its service revenue growth to achieve profitability.

Financial Highlights

debt To Equity
0
revenue
273.5 million
total Assets
1.03 billion
total Debt
0
net Income
-233.1 million

Revenue Breakdown

SegmentRevenueGrowth
Product198.8 million-11%
Service and Other74.7 million10%

Key Numbers

Key Players & Entities

FAQ

When did PACIFIC BIOSCIENCES OF CALIFORNIA, INC. file this 10-K?

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filed this Annual Report (10-K) with the SEC on February 28, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB).

Where can I read the original 10-K filing from PACIFIC BIOSCIENCES OF CALIFORNIA, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by PACIFIC BIOSCIENCES OF CALIFORNIA, INC..

What are the key takeaways from PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s 10-K?

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filed this 10-K on February 28, 2024. Key takeaways: PacBio reported total revenue of $273.5 million for the fiscal year ended December 31, 2023.. Product revenue for 2023 was $198.8 million, a decrease of 11% compared to $223.4 million in 2022.. Service and other revenue increased by 10% to $74.7 million in 2023 from $68.0 million in 2022..

Is PACIFIC BIOSCIENCES OF CALIFORNIA, INC. a risky investment based on this filing?

Based on this 10-K, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. presents a moderate-risk profile. The company reported an increased net loss in 2023 ($233.1M vs $217.7M in 2022) and a decrease in product revenue, indicating potential headwinds in core business segments.

What should investors do after reading PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s 10-K?

Investors should monitor the company's ability to reverse the product revenue decline and leverage its service revenue growth to achieve profitability. The overall sentiment from this filing is mixed.

How does PACIFIC BIOSCIENCES OF CALIFORNIA, INC. compare to its industry peers?

Pacific Biosciences of California, Inc. operates in the life sciences industry, focusing on developing and commercializing sequencing technologies for biological research and clinical applications.

Are there regulatory concerns for PACIFIC BIOSCIENCES OF CALIFORNIA, INC.?

As a publicly traded company, PacBio is subject to SEC regulations and reporting requirements, including the annual filing of a 10-K.

Industry Context

Pacific Biosciences of California, Inc. operates in the life sciences industry, focusing on developing and commercializing sequencing technologies for biological research and clinical applications.

Regulatory Implications

As a publicly traded company, PacBio is subject to SEC regulations and reporting requirements, including the annual filing of a 10-K.

What Investors Should Do

  1. Analyze the drivers behind the 11% decrease in product revenue for 2023.
  2. Evaluate the sustainability and growth potential of the 10% increase in service and other revenue.
  3. Assess the company's cash burn rate and runway given the increased net loss in 2023.

Key Dates

Year-Over-Year Comparison

This 10-K filing covers the fiscal year ending December 31, 2023, providing updated financial and operational data compared to the previous year's filings.

Filing Stats: 4,261 words · 17 min read · ~14 pages · Grade level 17.2 · Accepted 2024-02-28 16:28:25

Key Financial Figures

Filing Documents

Business

Business 3 Item 1A.

Risk Factors

Risk Factors 13 Item 1B. Unresolved Staff Comments 52

C

Item 1 C . C yber sec urity 52 Item 2.

Properties

Properties 53 Item 3.

Legal Proceedings

Legal Proceedings 54 Item 4. Mine Safety Disclosures 55 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 56 Item 6. [Reserved] 57 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 57 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 69 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 70 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 111 Item 9A.

Controls and Procedures

Controls and Procedures 111 Item 9B. Other Information 113 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 113 PART III Item 10. Directors, Executive Officers and Corporate Governance 113 Item 11.

Executive Compensation

Executive Compensation 113 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 113 Item 13. Certain Relationships and Related Transactions, and Director Independence 113 Item 14. Principal Accountant Fees and Services 113 PART IV Item 15. Exhibits, Financial Statement Schedules 113 Item 16. Form 10-K Summary 116

Signatures

Signatures 117 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K, including the sections titled "Business," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" contain or may contain forward-looking statements that are based on the beliefs and assumptions of the management of Pacific Biosciences of California, Inc. (the "Company," "we," "us," or "our") and on information currently available to our management. The statements contained in this Annual Report on Form 10-K that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and include, but are not limited to: the availability, uses, accuracy, sensitivity, advantages, compatibility, pricing, specifications, quality, or performance of, or benefits or expected benefits or using, our products or technologies, including the Revio TM and Onso TM systems; our current and future products; our strategic and commercial plans, including our expectations for Revio and Onso systems; our market opportunity, including market size and expected market growth; our expectations regarding the conversion of backlog to revenue and the pricing and gross margin for products; our manufacturing plans including developing and scaling of manufacturing and delivery of our products; our research and development plans; the anticipated impact of catastrophic events, including health epidemics or pandemics and military or other armed conflicts, on our business, business plans and results of operations; our product development plans, roadmaps, and objectives, including, among other things, statements relating to future uses, quality, or performance of, or benefits of using, products or technologies, updates, or improvements of our products; our intentions regard

BUSINESS

ITEM 1. BUSINESS Overview We are a premier life science technology company that is designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing technology and our Sequencing by Binding (SBB ) short-read sequencing technology. Our products address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Long-read sequencing was recognized by the journal Nature Methods as its "method of the year" for 2022 for its contributions to biological understanding and future potential. Our focus is on creating some of the world`s most advanced sequencing systems to provide our customers the most complete and accurate view of genomes, transcriptomes, and epigenomes. Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies. Recent Developments In 2023, we commercially released two new sequencing platforms, Revio TM and Onso TM . Revio is a new long-read sequencing system designed to enable the use of HiFi sequencing for large studies in human genetics, cancer research, and agricultural genomics. Commercial shipments for Revio commenced in the first quarter of 2023, and 173 systems have since been shipped to more than twenty countries as of December 31, 2023. We released SMRT Link 13.0 software on the Revio system which includes the adaptive loading feature for consistent run performa

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing